Abstract:Glioblastoma (GBM) is the most aggressive tumour originating from the brain. At present, surgery combined with radiotherapy and chemotherapy is the main therapy modality for GBM. However, the prognosis for patients with GBM still remains poor. It is known that malignant glioblastoma cells are more susceptible to unfolded protein response (UPR) and ERs because of high level of protein synthesis. Therefore, the potential vulnerability of the ER in GBM cells via the disturbance of UPR may hold therapeutic promise for GBM. We isolated a class of aspergin derivatives from Eurotium cristatum through polyketide synthase (PKS) and phosphatase (PTase)-dependent genome mining-aided biosynthesis. A methodology was developed to screen anti-glioma compounds in primary culture cells as well as Temozolomide (TMZ)-resistant ERs-sensitive cells. Apoptotic ability of decitabine (DAC) was tested by electron microscopy. Confocal scanning was performed to investigate the DAC-induced UPR and harmful autophagy in ER. Seahorse Mito-Stress test and electron transport chain (ETC) activity assay were used to evaluate the oxygen consumption rate, ATP production, and OXPHOS effect of DAC-treated cells. Xenograft mouse models was established to confirm the anti-glioma effect of DAC on tumour growth. Firstly, the data indicated that DAC induced dysfunction of ER-mitochondria communication as well as ERs-dependent apoptosis via disrupting the mitochondrion-associated ER membrane (MAM) machinery. Secondly, it was demonstrated that DAC blocked degradation of PACS2 resulting in over-link of MAM networks and destabilization of the ER-mitochondria crosstalk. Thirdly, accumulation of PACS2 promoted translocation of Bid to mitochondria, thereby facilitating disturbances in OXPHOS-dependent energy metabolism. Furthermore, we observed high cIAP1 and low PACS2 expression levels in glioma tissues, Finally, it was confirmed that DAC-induced suppression of PACS2 degradation contributed to anti-glioma activity in vivo. In conclusion, these findings suggested that DAC might be a candidate for the treatment of ERs-sensitive malignant gliomas through negatively regulating cIAP-mediated degradation of PACS2. Moreover, our study provides new insights that ER-mitochondria contact sites might be therapeutic targets of GBM.

CEBPB upregulates P4HA2 to promote the malignant biological behavior in IDH1 wildtype glioma

PSMC2/E2F1 Axis Promotes the Development and Progression of Glioma

P4HA2 Promotes Epithelial-to-Mesenchymal Transition and Glioma Malignancy through the Collagen-Dependent PI3K/AKT Pathway

CPEB2 m6A Methylation Regulates BTB Permeability via Affecting Splicing Factor SRSF5 Stability

EZH2 Interacts with HP1BP3 to Epigenetically Activate WNT7B That Promotes Temozolomide Resistance in Glioblastoma.

CBX2 enhances the progression and TMZ chemoresistance of glioma via EZH2-mediated epigenetic silencing of PTEN expression

IDH1-mutant metabolite D-2-hydroxyglutarate inhibits proliferation and sensitizes glioma to temozolomide via down-regulating ITGB4/PI3K/AKT

GSK3 Palmitoylation Mediated by ZDHHC4 Promotes Tumorigenicity of Glioblastoma Stem Cells in Temozolomide-Resistant Glioblastoma Through the EZH2-STAT3 Axis

CHIP-mediated ubiquitin degradation of BCAT1 regulates glioma cell proliferation and temozolomide sensitivity

P4HB and PDIA3 Are Associated with Tumor Progression and Therapeutic Outcome of Diffuse Gliomas

CEBPD is a master transcriptional factor for hypoxia regulated proteins in glioblastoma and augments hypoxia induced invasion through extracellular matrix-integrin mediated EGFR/PI3K pathway

Tumor-promoting function of PIMREG in glioma by activating the β-catenin pathway

PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition

Molecular Characterization of AEBP1 at Transcriptional Level in Glioma

CPEB2 m6A methylation regulates blood–tumor barrier permeability by regulating splicing factor SRSF5 stability

E3 ligase MAEA-mediated ubiquitination and degradation of PHD3 promotes glioblastoma progression

12P Genome Mining-Aided Biosynthesis Overcomes Temozolomide-resistant Glioblastoma Via Negatively Regulating Ciap-Mediated Degradation of PACS2 and ER-mitochondria Contact Sites

PDIA4 promotes glioblastoma progression via the PI3K/AKT/m-TOR pathway

Pericytes augment glioblastoma cell resistance to temozolomide through CCL5-CCR5 paracrine signaling

UBE2D3 Activates SHP-2 Ubiquitination to Promote Glycolysis and Proliferation of Glioma via Regulating STAT3 Signaling Pathway

P4HA2 is associated with prognosis, promotes proliferation, invasion, migration and EMT in glioma